Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in vaccines & infectious disease will be read downstream.
Vaccines & Infectious Disease
ICG works across vaccine and infectious-disease environments where epidemiology, clinical differentiation, manufacturing capacity, national procurement, recommendations, and launch sequencing form one decision system.
The work includes vaccine competitive intelligence, trial and regulatory assessment, capacity and supply analysis, tender and procurement pathways, pre-launch strategy, emerging-market commercialization, and longitudinal monitoring.
Population Logic Meets Supply Reality.
A vaccine market is governed simultaneously by evidence, recommendations, schedule position, manufacturing yield, supply allocation, procurement, public-health priorities, and confidence among clinicians and populations.
ICG reconstructs those systems across national and commercial settings to identify how an asset can move from development into recommendation, purchase, distribution, and sustained use.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across vaccines & infectious disease.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Competitive Development Landscape for Next-Generation Pneumococcal Vaccines
- Development and Launch Assessment of RSV Vaccines in the United States and Europe
- Clinical-Development Assessment of Meningococcal Vaccine Portfolios
- Development Landscape for Escherichia coli Vaccines
- Trial and Regulatory Assessment for Dengue Vaccines in Latin America and Asia
Regulatory, Access & Adoption
- Regulatory and Recommendation Pathways for RSV Vaccines in Emerging Markets
- National-Immunization and Tender Architecture for Pneumococcal Vaccines
- Regulatory and Procurement Assessment for Influenza Vaccines in Germany
- Access and Uptake Architecture for Dengue Vaccines Across Selected Markets
- Public-Health and Commercial Pathways for Pediatric Vaccines in Emerging Markets
Launch & Commercial Architecture
- Pre-Launch, Capacity and Commercialization Assessment of Respiratory and Pediatric Vaccines in Developed and Emerging Markets
- RSV Vaccine Portfolio Assessment in China and Selected Global Markets
- Launch Strategy for Novel Pneumococcal Vaccines Outside the United States and Europe
- Pre-Launch Assessment of Meningococcal Vaccines in the United States and Selected International Markets
- Commercialization Architecture for Influenza Vaccines in Europe and Emerging Markets
Manufacturing, Delivery & Systems
- Manufacturing-Capacity and Commercialization Assessment of Influenza Vaccines
- mRNA Vaccine Manufacturing and Scale-Up Architecture
- Capacity, Prioritization and Supply Assessment for High-Dose Influenza Vaccines
- Pandemic-Preparedness Architecture Across mRNA and Protein-Based Platforms
- Supply and Market-Entry Assessment for Anti-Infectives in Latin America and Asia
Longitudinal Monitoring & Portfolio
- Longitudinal Pre-Launch and Competitive Assessment of Dengue Vaccines in Latin America and Asia
- Multi-Year Monitoring of Pneumococcal Vaccine Portfolios
- Longitudinal Assessment of RSV Preventive Products in Developed and Emerging Markets
- Competitive Monitoring Across Influenza, COVID-19 and Combination-Vaccine Programs
Vaccines & Infectious Disease Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.